SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-24-060497
Filing Date
2024-05-15
Accepted
2024-05-15 16:19:41
Documents
81
Period of Report
2024-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q mreo-20240331.htm   iXBRL 10-Q 1469594
2 EX-31.1 mreo-ex31_1.htm EX-31.1 21137
3 EX-31.2 mreo-ex31_2.htm EX-31.2 21106
4 EX-32.1 mreo-ex32_1.htm EX-32.1 7349
5 EX-32.2 mreo-ex32_2.htm EX-32.2 7089
  Complete submission text file 0000950170-24-060497.txt   8171856

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT mreo-20240331.xsd EX-101.SCH 1538834
85 EXTRACTED XBRL INSTANCE DOCUMENT mreo-20240331_htm.xml XML 1404015
Mailing Address ONE CAVENDISH PLACE FOURTH FLOOR LONDON X0 W1G0QF
Business Address ONE CAVENDISH PLACE FOURTH FLOOR LONDON X0 W1G0QF 4403330237300
Mereo BioPharma Group plc (Filer) CIK: 0001719714 (see all company filings)

IRS No.: 000000000 | State of Incorp.: X0 | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38452 | Film No.: 24951158
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)